FIELD: pharmaceuticals; medicine.
SUBSTANCE: objects 1 and 2 are a liquid pharmaceutical composition containing from 118 to 128 mg/ml of the bispecific antibody to VEGF/ANG2, which is faricimab, from 15 to 35 mM sodium chloride, from 15 to 25 mM histidine acetate buffer, at a pH of 5.5 to 6.1, including for use in the treatment of vascular eye disease. Object 3 is a method for obtaining a pharmaceutical composition. Objects 4 and 5 are a bottle and a pre-filled syringe containing a pharmaceutical composition. Object 6 is a lyophilized form of a liquid pharmaceutical composition.
EFFECT: low viscosity and low turbidity of the composition at a high concentration of the antibody.
17 cl, 14 dwg, 16 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| MODIFIED J-STRAIN | 2015 |
|
RU2761118C2 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2019 |
|
RU2747735C2 |
| BISPECIFIC ANTIGEN-BINDING POLYPEPTIDES | 2015 |
|
RU2723940C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| IMMUNOGLOBULIN WITH TANDEM ARRANGEMENT OF FAB FRAGMENTS AND APPLICATION THEREOF | 2014 |
|
RU2769133C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
